FDA approves H1N1 vaccine, paves way for large-scale U.S. vaccination campaign

HHS Secretary Kathleen Sebelius announced Tuesday during a House Energy and Commerce Committee hearing that H1N1 (swine flu) vaccines produced by four manufacturers — CSL Ltd., Novartis, Sanofi-Pasteur and Medimmune — had won FDA approval, paving the way for a U.S. large-scale vaccination campaign, The Wall Street Journal reports. The application for GlaxoSmithKline PLC's vaccine is still being considered (Dooren/Favole, 9/15).

According to CQ HealthBeat, HHS anticipates having some supplies of H1N1 vaccine available as early as October 5 (Attias, 9/15), but "[t]he bulk of vaccine will start arriving Oct. 15, and Sebelius said it should be available at 90,000 sites around the country," The Associated Press/TIME reports. "'We will have enough vaccine available for everyone' eventually, Sebelius said — everyone who wants it, that is." The U.S. government currently has contracts to buy 195 million doses of the H1N1 vaccine, but will buy more if demand is high, Sebelius explained (Neergaard, 9/15).

The large-scale vaccination campaign, scheduled to begin in mid-October, will first target those at greatest risk from H1N1, including health care workers, pregnant women and young people ages 6 months to 24 years. Reuters writes: "H1N1 vaccines will be free, Sebelius said, but some healthcare providers may charge an administration fee. The federal government is planning to spend about $1.4 billion for states and hospitals to prepare for the virus, she added" (Heavey, 9/15).

This is part of Kaiser Health News' Daily Reports - a summary of health policy coverage from more than 300 news organizations. The full summary of the day's news can be found here and you can sign up for e-mail subscriptions to the Daily Reports here. In addition, our staff of reporters and correspondents file original stories each day, which you can find on our home page.


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
VALANX Biotech and Fina Biosolutions Introduce ClickCRM for Rapid Conjugate Vaccine Development